Medicago and InterveXion Team Up to Develop Drug Abuse Therapies

Medicago and InterveXion Therapeutics have formed a multi-year product co-development collaboration, which will use Medicago's Proficia Protein Technology for the production of monoclonal antibodies therapeutics designed to treat drug abuse. InterveXion has received a $3 million grant to conduct clinical trials for the first antibody treatment for addiction to the drug phencyclidine, or PCP.

()a href="http://www.pharmaceutical-business-review.com/article_news.asp?guid=EFC49A98-244A-4CE3-BA97-D49C5AB58917" target="_blank">Pharmaceutical Business Review Online